Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00301756 · OUTCOME

Progression-free Survival

Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors · Source last updated 2018-08-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Duration of time from start of treatment to time of progression, assessed up to 5 years

What was measured

Computed using the Kaplan-Meier method. Ninety-five percent confidence intervals will be constructed and selected results will be illustrated using figures and plots.

Groups in this outcome

Treatment (Enzyme Inhibitor Therapy)

Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. belinostat: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Enzyme Inhibitor Therapy)12

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Enzyme Inhibitor Therapy)13.4Not reported5.6NA95% confidence interval, 5.6 to not reached
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        95% confidence interval, 5.6 to not reached
        group Id
        OG000
        lower Limit
        5.6
        upper Limit
        NA
        value
        13.4
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    units
    Participants
description
Computed using the Kaplan-Meier method. Ninety-five percent confidence intervals will be constructed and selected results will be illustrated using figures and plots.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. belinostat: Given IV
    id
    OG000
    title
    Treatment (Enzyme Inhibitor Therapy)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Duration of time from start of treatment to time of progression, assessed up to 5 years
title
Progression-free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice